Efficacy and Safety of Mitiglinide in Korean Type 2 Diabetic Patients: Prospective Randomised Multicenter Comparative Phase III Study

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Journal of Korean Diabetes Association

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4093/JKDA.2007.31.2.163
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Study of nateglinide in Japan: Long-term treatment of patients with type 2 diabetes

  2006cited by this paper
• [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].

  2005cited by this paper
• 新規速効型インスリン分泌促進薬ミチグリニドカルシウム水和物（グルファスト®錠）の薬理学的特徴および臨床試験成績

  2004cited by this paper
• The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium.

  2004cited by this paper
• Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus

  2004cited by this paper
• Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy

  2004cited by this paper
• [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset].

  2004cited by this paper
• Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance

  2004cited by this paper
• [Nateglinide and mitiglinide].

  2003cited by this paper
• Pharmacology of the Meglitinide Analogs

  2003cited by this paper
• Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

  2003cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.

  2001cited by this paper
• Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence

  2001cited by this paper
• Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus

  2000cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Effect of glycemia on mortality in Pima Indians with type 2 diabetes.

  1999cited by this paper
• Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

  1999cited by this paper
• The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells.

  1999cited by this paper
• Tissue Selectivity of Antidiabetic Agent Nateglinide: Study on Cardiovascular and β-Cell KATP Channels

  1999cited by this paper
• Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM.

  1998cited by this paper
• Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study

  1998cited by this paper
• Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Nonfasting Plasma Glucose is a Better Marker of Diabetic Control Than Fasting Plasma Glucose in Type 2 Diabetes

  1997cited by this paper
• Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs.

  1995cited by this paper
• Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning.

  1995cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage.

  1991cited by this paper
• Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.

  1967cited by this paper
• Plasma Insulin Concentrations in Nondiabetic and Early Diabetic Subjects: Determinations by a New Sensitive Immuno-assay Technic

  1960cited by this paper

• Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association

  2018cites this paper
• Monotherapy in patients with type 2 diabetes mellitus

  2017cites this paper
• Monotherapy in Patients with Type 2 Diabetes Mellitus

  2017cites this paper